CoChat
Sign Up
Cited by 51Cervical Cancer and HPV ResearchWomen's cancer prevention and managementEndometrial and Cervical Cancer Treatments

Age-specific occurrence of HPV16- and HPV18-related cervical cancer

Open access
de Sanjose, Silvia, Wheeler, Cosette M., Quint, Wim G.V., Hunt, William C., Joste, Nancy E., Alemany, Laia, Xavier Bosch, F., Myers, Evan R. +1 more·2013·Cancer Epidemiology, Biomarkers & Prevention
DOI 10.1158/1055-9965.epi-13-0053PMC PMC4306595
Open this paper in CoChat — free account

Abstract

The age-specific occurrence of cervical cancer related to human papillomavirus (HPV) genotypes HPV16 and HPV18, the two targeted by current HPV vaccines, is not well described. We therefore used data from two large, tissue-based HPV genotyping studies of cervical cancer, one conducted in New Mexico (n = 744) and an International study restricted to cancers (n = 1,729) from Europe, North America, and Australia to represent those regions with widely available cervical cancer screening facilities. HPV results were categorized as HPV16- or HPV18-positive (HPV16/18) versus other HPV genotype. We observed a decreasing proportion of HPV16/18-positive cancers with increasing age in the International study (Ptrend < 0.001) and New Mexico study (Ptrend < 0.001). There was no heterogeneity in the relationship between age of diagnosis and the proportion of HPV16/18-positive cancers between studies (P = 0.8). Combining results from the two studies (n = 2,473), the percentages of HPV16/18-positive cases were 77.0% [95% confidence interval (CI): 75.1%–78.9%] for women less than 65 years old and 62.7% [95% confidence interval (CI): 58.4%–66.9%] for women aged 65 and older (P < 0.001). In women who are under the age of 25 and have been vaccinated before becoming sexually active, the cervical cancer incidence is expected to be approximately 3.5 per million by 2020. HPV vaccination against HPV16/18 may have a greater impact on cervical cancers in women under 65 than in women aged 65 and older. These data will inform the age-specific impact of HPV vaccination and its integration with cervical cancer screening activities. Cancer Epidemiol Biomarkers Prev; 22(7); 1313–8. ©2013 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1055-9965.epi-13-0053

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 23

  1. [1]de SS Quint WG Alemany L Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010 11 11 1048 56 20952254
  2. [2]Romanowski B de Borba PC Naud PS Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009 374 9706 1975 85 19962185
  3. [3]Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007 356 19 1915 27 17494925
  4. [4]Garland SM Hernandez-Avila M Wheeler CM Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007 356 19 1928 43 17494926
  5. [5]Paavonen J Naud P Salmeron J Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009 374 9686 301 14 19586656
  6. [6]Dillner J Kjaer SK Wheeler CM Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010 341 c3493 doi: 10.1136/bmj.c3493.:c3493 20647284 PMC2907480 · DOI
  7. [7]Rowhani-Rahbar A Mao C Hughes JP Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 2009 27 41 5612 9 19647066 PMC2749988
  8. [8]Roteli-Martins CM Naud P De BP Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012 8 3 390 7 22327492
  9. [9]Hildesheim A Herrero R Wacholder S Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007 298 7 743 53 17699008
  10. [10]Haupt RM Wheeler CM Brown DR Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. Int J Cancer 2011 129 11 2632 42 21491420
  11. [11]Saslow D Solomon D Lawson HW American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012 62 3 147 72 22422631 PMC3801360
  12. [12]Wheeler CM Hunt WC Joste NE Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009 101 7 475 87 19318628 PMC2664090
  13. [13]Benard VB Watson M Castle PE Saraiya M Cervical carcinoma rates among young females in the United States. Obstet Gynecol 2012 120 5 1117 23 23090530 PMC4540330
  14. [14]Wheeler CM Kjaer SK Sigurdsson K The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009 199 7 936 44 19236277
  15. [15]National and state vaccination coverage among adolescents aged 13 through 17 years --- United States, 2010. MMWR Morb Mortal Wkly Rep 2011 60 1117 23 1117 23 21866084
  16. [16]Saslow D Solomon D Lawson HW American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012 62 3 147 72 22422631 PMC3801360
  17. [17]Mosher WD Chandra A Jones J Sexual behavior and selected health measures: men and women 15-44 years of age, United States, 2002. Adv Data 2005 362 1 55 16250464
  18. [18]Castle PE Carreon JD Practice improvement in cervical screening and management: symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Tract Dis 2010 14 3 238 340 20592562
  19. [19]Arbyn M Anttila A Jordan J European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document. Ann Oncol 2010 21 3 448 58 20176693 PMC2826099
  20. [20]Anttila A Ronco G Description of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer 2009 45 15 2685 708 19744852
  21. [21]Recommendations on screening for cervical cancer. CMAJ 2013 185 1 35 45 23297138 PMC3537778
  22. [22]Sasieni P Castanon A Cuzick J Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ 2009 339 b2968 doi: 10.1136/bmj.b2968.:b2968 19638651 PMC2718082 · DOI
  23. [24]Arbyn M Kyrgiou M Simoens C Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008 337 a1284 doi: 10.1136/bmj.a1284.:a1284 18801868 PMC2544379 · DOI

Cited by

Sorted by citations

Authors
de Sanjose, S., Wheeler, C. M., Quint, W. G. V., Hunt, W. C., Joste, N. E., Alemany, L., Xavier Bosch, F., Myers, E. R., & Castle, P. E.
Affiliations
  • Authors' Affiliations: 1IDIBELL, Institut Catalàd'Oncologia-Catalan Institute of Oncology, L'Hospitalet de, Llobregat; 2CIBER en Epidemiología y Salud Pública, Barcelona, Spain; 3Departments of Pathology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, House of Prevention Epidemiology (HOPE), Albuquerque, New Mexico; 4Division of Clinical and Epidemiological Research, Department of Obstetrics and Gynecology, Duke University; 5Global Cancer Initiative, Chestertown, Maryland; and 6DDL Diagnostic Laboratory, Voorburg, the Netherlands
  • Duke University (US)
Corresponding author
Castle, Philip E.
ORCID
Venue
Cancer Epidemiology, Biomarkers & Prevention
Publisher
American Association for Cancer Research (AACR)
Published
2013-07-01
Volume
22
Issue
7
Pages
1313-1318
ISSN
  • 1055-9965 (ISSN-L)
  • 1538-7755
DOI
10.1158/1055-9965.epi-13-0053
PMC
PMC4306595
OpenAlex
W2146647422
Cited by
51
References
0
Citations by year
2026: 1 · 2025: 1 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 2 · 2020: 6 · 2019: 3 · 2018: 4 · 2017: 7 · 2016: 5 · 2015: 8 · 2014: 4 · 2013: 1
FWCI
4.38
Type
journal article
Language
en
Open access
Locations
  • Cancer Epidemiology Biomarkers & Prevention (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Food and Drug Administration
  • National Institute of Allergy and Infectious Diseases (U19AI084081)
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
Keywords
cervical cancer, HPV16, HPV 18, human papillomavirus, age-specific incidence, HPV vaccination, HPV genotyping, cervical cancer screening, young women, New Mexico, international studies
MeSH terms
Adolescent, Adult, Age Factors, Aged, Uterine Cervical Neoplasms, Cross-Sectional Studies, Female, Humans, Middle Aged, New Mexico, Retrospective Studies, SEER Program, Papillomavirus Infections, Human papillomavirus 18, Human papillomavirus 16, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review